The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Neurostimulation Devices Market (2nd Edition), 2018-2030

  • Lowest Price Guaranteed From USD 3,499

  • Published
    September 2018

  • Pages
    639

  • View Count
    3214

Example Insights

   

 

Overview

In my opinion, deep brain stimulation is amongst the fastest growing segments within this domain. Although its current market is still at an infant stage, it is anticipated to evolve significantly in the coming 5-10 years, given the large number of innovative technologies that are currently under development

-President & CEO, a US-based small-sized device developer

The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of around USD 600 billion per year, in treatment costs and lost productivity. Further, it has been estimated that nearly 1 million people in America suffer from Parkinson’s disease, with approximately 60,000 new patients being diagnosed every year.Over the past few decades, the prevalence of such chronic disorders has grown at an alarming rate. In fact, a recent World Health Organization’s Global Burden of Disease study recognized these chronic conditions as one of the leading causes of deteriorating public health in the world. Such clinical conditions have often been shown to result in serious physical, cognitive and psychosocial consequences in patients.This indicates an urgent need for novel and effective treatment methods as the drawbacks of existing treatment options (such as high risk of addiction / abuse associated with long-term use of oral opioids, and complications due to complex surgical procedures) are substantial.

Extensive research in the field of neurostimulation has demonstrated the potential of this technique in providing therapeutic relief to a number of patients, who have developed resistance to conventional medication. Since the introduction of the first neurostimulation therapy in 1960s, their numerous observed benefits, such as reversible and minimally invasive nature of the procedures (to administer such treatments), targeted approach to therapeutic relief that can be modulated as well, provisions for integrating various safety mechanisms, and negligible use of opioids / other medications, have captured the interest of several stakeholders in the industry. In fact, since 2010, over 4,000 patents have been published in this domain, indicating the rapid pace at which research is being carried out. It is anticipated that such efforts are likely to boost the overall growth of this market in the coming years.

Scope of the Report

The ‘Neurostimulation Devices Market (2nd Edition), 2018-2030’ report features an extensive study of the current landscape and future outlook of the growing market for neurostimulation devices. The focus of this study is on invasive neurostimulation devices, such as devices for spinal cord stimulation (SCS), deep brain stimulation (DBS), spinal nerve stimulation (SNS), vagus nerve stimulation (VNS), other cranial nerve stimulation (Other CNS) and other variants of neurostimulation devices. Amongst other elements, the report features:

  • A detailed assessment of the overall landscape of neurostimulation devices market, featuring the contributions of various companies engaged in this domain and highlighting key device specifications (size, weight, battery type, battery life, number of electrodes, type of programming, and MRI compatibility), along with information on different types of neurostimulation devices, target therapeutic areas, and regulatory approvals received across various geographies.
  • A comprehensive product competitiveness analysis, taking into consideration the supplier power and specific device-related parameters, such as number of target indications, target nerves, regulatory approvals, and key device specifications.
  • Comprehensive profiles of developers of leading neurostimulation devices (shortlisted on the basis of the product competitiveness analysis), featuring an overview of the company, its financial information (if available), and a detailed description of the device(s). Each profile also includes a list of recent developments, highlighting the achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
  • An elaborate discussion on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). The information covers details on the payer mix, and the reimbursement processes of various public / private organizations across these geographies.
  • A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands across different device types, taking into consideration several aspects, such as strength / diversity of product portfolio, extent of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the players.
  • An in-depth analysis of the patents that have been published since 2013. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players (in terms of number of patents filed / granted), and patent benchmarking and valuation.
  • A comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.
  • An analysis of the partnerships that have been established in the recent past, covering product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others.
  • An analysis of investments made at various stages of product development / commercialization; these include seed financing, venture capital financing, debt financing and grants / awards received by the companies that are operating in this domain.
  • A comprehensive list of non-invasive neurostimulation devices, along with information on their developers, various types of non-invasive technologies used, target therapeutic areas, and development / approval status of the devices.
  • An elaborate discussion on the upcoming opportunities / trends in the field of neurostimulation devices that are likely to impact the evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for neurostimulation devices. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030. The report provides sales forecasts for the overall neurostimulation devices market with detailed market segmentation on the basis of type neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive compulsive disorder, overactive bladder, sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were also influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies)
  • Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences)
  • Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical)
  • Laura Tyler Perryman (Chief Executive Officer, Stimwave)
  • Luca Ravagnan (Chief Executive Officer, WISE)
  • Steve Goedeke (President and Chief Executive Officer, Cardionomic)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2  is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the neurostimulation devices market in the mid to long term.

Chapter 3  is an introductory chapter that presents a general overview of the epidemiology and the growing prevalence of chronic clinical conditions, along with information on the limitations of conventional treatment methods. Further, it features a detailed discussion on neurostimulation devices, including a comprehensive history of development, information on their basic components and principle of operation, and associated advantages / challenges. It also features a discussion on the key types of neurostimulation devices, including SCS, DBS, SNS, VNS, Other CNS, and other device types, featuring information on the potential applicability of these devices across different disease indications. Further, the chapter features a discussion on the key growth drivers and road blocks related to neurostimulation and its use in treating various neurological conditions.

Chapter 4  provides a detailed description on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). Further, it provides information on the payer mix, and details of the reimbursement processes of various public / private organizations across different geographies.

Chapter 5  includes information on more than 125 invasive neurostimulation devices that are either commercialized or under development for the treatment of different disorders. It features detailed analyses of these devices based on key specifications (including size, weight, battery type, battery longevity, number of electrodes, and MRI compatibility), Further, we have provided information on different types of neurostimulation devices, target nerves, target therapeutic areas, and regulatory approvals received across various geographies. The chapter also highlights the contributions of various companies engaged in this domain, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 6  provides a detailed review of SCS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters, such as number of target indications, target nerves, regulatory approvals, and key specifications of the devices (including size, weight, battery type, battery longevity, number of electrodes, type of programming, and MRI compatibility). In addition, the chapter includes elaborate profiles of the developers of leading SCS devices ( shortlisted   on the basis of device competitiveness analysis scores ); each profile features an overview of the company, its financial information ( if available ), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 7  provides a detailed review of DBS devices, along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents a comprehensive 2 X 2 matrix to compare device competitiveness, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading DBS devices ( shortlisted on the basis of device competitiveness analysis scores ); each profile features an overview of the company, its financial information ( if available ), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 8  provides a detailed review of PNS devices (including SNS, VNS and Other CNS devices), along with information on their historical evolution and associated surgical procedures (for implantation). The chapter also presents three comprehensive 2 X 2 matrices to compare device competitiveness within each type of PNS devices, by taking into consideration the supplier power (based on size of employee base) and certain device-related parameters. In addition, the chapter includes elaborate profiles of the developers of leading devices within each type ( shortlisted on the basis of respective device competitiveness analysis scores ); each profile features an overview of the company, its financial information ( if available ), detailed description of the device(s) and the recent developments and future outlook with respect to the specific device(s) / overall neurostimulation domain.

Chapter 9  provides an elaborative brand positioning analysis of the leading industry players ( shortlisted on the basis of strength of product portfolio ) highlighting the current perceptions regarding their proprietary brands across different device types. The analysis takes into consideration several aspects, such as strength / diversity of product portfolio, strength of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the companies.

Chapter 10  provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For the purpose of this analysis, we considered those patents that have been published since 2013 related to the neurostimulation domain. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players, and patent benchmarking and valuation.

Chapter 11  provides a comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.

Chapter 12  features an elaborate discussion and analysis of the various partnerships / collaborations that have been inked amongst players in this market. It includes a brief description on the various types of partnership models (such as product development / commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers / acquisitions, and others) that have been employed by stakeholders in this domain, and analysis on the trend of partnerships inked since 2015. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances related to neurostimulation devices. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 13  provides information on the funding instances and investments that have been made in the neurostimulation domain. The chapter includes details on various types of investments (such as seed financing, venture funding, debt financing and grants) received by companies between 2015 and mid-2018, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 14  features a comprehensive market forecast, highlighting the future potential of neurostimulation devices till 2030 based on multiple parameters, such as prices of devices, indication / region specific adoption trends, and competitive landscape. We have segmented the market on the basis of type of neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson’s disease, obsessive compulsive disorder, overactive bladder, and sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan). We have adopted a  bottom up  approach, backed by robust data and credible inputs from primary research, to estimate the likely size of the market, both in terms of value (USD billion) and volume (number of devices).

Chapter 15  presents a discussion on the upcoming opportunities / trends in the field of neurostimulation devices that are likely to impact the future evolution of this market over the coming years. These include (but not limited to) development of devices against unexplored therapeutic areas, integration of novel and advanced features, launch in different geographies, increased utilization of real world evidence-based insights, and implementation of cybersecurity measures in the devices.

Chapter 16  is a collection of executive insights of the discussions that were held key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Dave Rosa (President and Chief Executive Officer, NeuroOne Medical Technologies), Deborah Schmalz (Vice President, Regulatory Affairs, Clinical Research and Compliance, ReShape Lifesciences) and Diane Utzman-O’Neill (Vice President, Marketing, ReShape Lifesciences), Jan Pieter Heemels (Vice President, Commercial Operations, Mainstay Medical), Laura Tyler Perryman (Chief Executive Officer, Stimwave), Luca Ravagnan (Chief Executive Officer, WISE), and Steve Goedeke (President and Chief Executive Officer, Cardionomic)

Chapter 17  is an appendix, which provides a comprehensive list of non-invasive neurostimulation devices, along with information on their developers, types of non-invasive neurostimulation technologies, target therapeutic areas, and development / approval status of the devices.

Chapter 18  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 19  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. An Overview of the Nervous System
3.2. Neurological Impairment
3.2.1. Global Burden of Neurological Disorders
3.2.2. Conventional Treatment Methods for Neurological Disorders
 
3.3. An Overview of Neuromodulation
3.4. Neurostimulation Devices
3.4.1. Historical Development
3.4.2. General Components and Working Principle
 
3.4.3. Types of Neurostimulation Devices
3.4.3.1. Spinal Cord Stimulation
3.4.3.2. Deep Brain Stimulation
3.4.3.3. Peripheral Nerve Stimulation
3.4.3.3.1. Spinal Nerve Stimulation
3.4.3.3.2. Vagus Nerve Stimulation
3.4.3.3.3. Other Cranial Nerve Stimulation
3.4.3.4. Comparison of Different Types
 
3.4.4. Advantages and Limitations
3.4.5. Potential Applications
3.4.6. Growth Drivers and Roadblocks
3.5. Social Media Trends Related to Neurostimulation Devices
 
4. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES
4.1. Chapter Overview
4.2. General Regulatory and Reimbursement Guidelines for Medical Devices
4.3. Regulatory and Reimbursement Landscape in North America
4.3.1. The US Scenario
4.3.1.1. Regulatory Authority
4.3.1.2. Review / Approval Process
4.3.1.3. Reimbursement Landscape
4.3.1.3.1. Payer Mix
4.3.1.3.2. Reimbursement Process
 
4.3.2. The Canadian Scenario
4.3.2.1. Regulatory Authority
4.3.2.2. Review / Approval Process
4.3.2.3. Reimbursement Landscape
4.3.2.3.1. Payer Mix
4.3.2.3.2. Reimbursement Process
 
4.4. Regulatory and Reimbursement Landscape in Europe
4.4.1. Overall Scenario
4.4.1.1. Regulatory Authority
4.4.1.2. Review / Approval Process
 
4.4.2. The UK Scenario
4.4.2.1. Reimbursement Landscape
4.4.2.1.1. Payer Mix
4.4.2.1.2. Reimbursement Process
 
4.4.3. The German Scenario
4.4.3.1. Reimbursement Landscape
4.4.3.1.1. Payer Mix
4.4.3.1.2. Reimbursement Process
 
4.4.4. The French Scenario
4.4.4.1. Reimbursement Landscape
4.4.4.1.1. Payer Mix
4.4.4.1.2. Reimbursement Process
 
4.4.5. The Spanish Scenario
4.4.5.1. Reimbursement Landscape
4.4.5.1.1. Payer Mix
4.4.5.1.2. Reimbursement Process
 
4.4.6. The Italian Scenario
4.4.6.1. Reimbursement Landscape
4.4.6.1.1 Payer Mix
4.4.6.1.2. Reimbursement Process
 
4.5. Regulatory and Regulatory Landscape in Asia-Pacific
4.5.1. The Australian Scenario
4.5.1.1. Regulatory Authority
4.5.1.2. Review / Approval Process
4.5.1.3. Reimbursement Landscape
4.5.1.3.1. Payer Mix
4.5.1.3.2. Reimbursement Process
 
4.5.2. The Chinese Scenario
4.5.2.1. Regulatory Authority
4.5.2.2. Review / Approval Process
4.5.2.3. Reimbursement Landscape
4.5.2.3.1. Payer Mix
4.5.2.3.2. Reimbursement Process
 
4.5.3. The Japanese Scenario
4.5.3.1. Regulatory Authority
4.5.3.2. Review / Approval Process
4.5.3.3. Reimbursement Landscape
4.5.3.3.1. Payer Mix
4.5.3.3.2. Reimbursement Process
 
5. CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Neurostimulation Devices: Overall Market Landscape
5.2.1. Distribution by Year of Establishment
5.2.2. Distribution by Geographical Location
5.2.3. Distribution by Size of Developers
5.2.4. Distribution by Developers
5.2.5. Distribution by Type of Devices
5.2.6. Distribution by Target Nerve
5.2.7. Distribution by Therapeutic Areas
5.2.8. Distribution by Development / Approval Status
5.2.9. Distribution by Size
5.2.10. Distribution by Weight
5.2.11. Distribution by Battery Type
5.2.12. Distribution by Battery Longevity
5.2.13. Distribution by Number of Electrodes
5.2.14. Distribution by MRI Compatibility
 
6. SPINAL CORD STIMULATION
6.1. Chapter Overview
6.2. Overview of SCS Devices
6.2.1. Historical Development
6.2.2. Associated Surgical Procedures
6.3. Device Competitiveness Analysis
 
6.4. Key Device Developers
6.4.1. Medtronic
6.4.1.1. Chapter Overview
6.4.1.2. Financial Information
6.4.1.3. Device Description: Intellis™
6.4.1.4. Recent Developments and Future Outlook
 
6.4.2. Boston Scientific
6.4.2.1. Chapter Overview
6.4.2.2. Financial Information
6.4.2.3. Device Description: Precision™ Plus
6.4.2.4. Recent Developments and Future Outlook
 
6.4.3. Stimwave
6.4.3.1. Chapter Overview
6.4.3.2. Financial Information
6.4.3.3. Device Description: Freedom-8A, Freedom-4
6.4.3.4. Recent Developments and Future Outlook
 
6.4.4. Nevro
6.4.4.1. Chapter Overview
6.4.4.2. Financial Information
6.4.4.3. Device Description: Senza
6.4.4.4. Recent Developments and Future Outlook
 
7. DEEP BRAIN STIMULATION
7.1. Chapter Overview
7.2. Overview of DBS Devices
7.2.1. Historical Development
7.2.2. Associated Surgical Procedures
7.3. Device Competitiveness Analysis
 
7.4. Key Device Developers
7.4.1. Medtronic
7.4.1.1. Chapter Overview
7.4.1.2. Financial Information
7.4.1.3. Device Description: Activa™ PC, Activa™ SC, Activa™ RC
7.4.1.4. Recent Developments and Future Outlook
 
7.4.2. Boston Scientific
7.4.2.1. Chapter Overview
7.4.2.2. Financial Information
7.4.2.3. Device Description: Vercise™ DBS, Vercise Gevia™
7.4.2.4. Recent Developments and Future Outlook
 
7.4.3. Beijing PINS Medical
7.4.3.1. Chapter Overview
7.4.3.2. Financial Information
7.4.3.3. Device Description: PINS™ DBS System
7.4.3.4. Recent Developments and Future Outlook
 
7.4.4. Abbott (St. Jude Medical)
7.4.4.1. Chapter Overview
7.4.4.2. Financial Information
7.4.4.3. Device Description: Brio™
7.4.4.4. Recent Developments and Future Outlook
 
8. PERIPHERAL NERVE STIMULATION
8.1. Chapter Overview
8.2. Overview of PNS Devices
8.2.1. Historical Development
8.2.2. Associated Surgical Procedures
 
8.3. Spinal Nerve Stimulation
8.3.1. Device Competitiveness Analysis
8.3.2. Key Device Developers
8.3.2.1. Axonics Modulation Technologies
8.3.2.1.1. Chapter Overview
8.3.2.1.2. Financial Information
8.3.2.1.3. Device Description: Axonics r-SNM™ System
8.3.2.1.4. Recent Developments and Future Outlook
 
8.3.2.2. BrainsGate
8.3.2.2.1. Chapter Overview
8.3.2.2.2. Financial Information
8.3.2.2.3. Device Description: Ischemic Stroke System™
8.3.2.2.4. Recent Developments and Future Outlook
 
8.3.2.3. Medtronic
8.3.2.3.1. Chapter Overview
8.3.2.3.2. Financial Information
8.3.2.3.3. Device Description: InterStim II
8.3.2.3.4. Recent Developments and Future Outlook
 
8.4. Vagus Nerve Stimulation
8.4.1. Device Competitiveness Analysis
8.4.2. Key Device Developers
8.4.2.1. LivaNova
8.4.2.1.1. Chapter Overview
8.4.2.1.2. Financial Information
8.4.2.1.3. Device Description: Pulse, Pulse Duo, AspireHC, AspireSR, SenTiva
8.4.2.1.4. Recent Developments and Future Outlook
 
8.4.2.2. SetPoint Medical
8.4.2.2.1. Chapter Overview
8.4.2.2.2. Financial Information
8.4.2.2.3. Device Description: Unnamed Bioelectronic Platform
8.4.2.2.4. Recent Developments and Future Outlook
 
8.4.2.3. Synergia Medical
8.4.2.3.1. Chapter Overview
8.4.2.3.2. Financial Information
8.4.2.3.3. Device Description: NAOS Platform
8.4.2.3.4. Recent Developments and Future Outlook
 
8.5. Other Cranial Nerve Stimulation
8.5.1. Device Competitiveness Analysis
8.5.2. Key Device Developers
8.5.2.1. Bioness
8.5.2.1.1. Chapter Overview
8.5.2.1.2. Device Description: StimRouter
8.5.2.1.3. Recent Developments and Future Outlook
 
8.5.2.2. Medtronic
8.5.2.2.1. Chapter Overview
8.5.2.2.2. Financial Information
8.5.2.2.3. Device Description: Intellis™
8.5.2.2.4. Recent Developments and Future Outlook
 
8.5.2.3. Nyxoah
8.5.2.3.1. Chapter Overview
8.5.2.3.2. Financial Information
8.5.2.3.3. Device Description: Genio™
8.5.2.3.4. Recent Developments and Future Outlook
 
8.5.2.4. BlueWind Medical
8.5.2.4.1. Chapter Overview
8.5.2.4.2. Device Description: RENOVA™, VIVENDI™
8.5.2.4.3. Recent Developments and Future Outlook
 
9. BRAND POSITIONING ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Brand Positioning Matrices of Key Industry Players
9.3.1. Abbott (St. Jude Medical)
9.3.2. Boston Scientific
9.3.3. LivaNova
9.3.4. Medtronic
9.3.5. Stimwave
 
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Neurostimulation Devices: Patent Analysis
10.3.1. Analysis by Publication Year
10.3.2. Analysis by Geographical Location
10.3.3. Analysis by CPC Classifications
10.3.4. Emerging Areas
10.3.5. Leading Players by Number of Patents
 
10.4. Neurostimulation Devices: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.4.1.1. Boston Scientific and Medtronic
10.4.1.2. Other Leading Patent Assignees
10.4.2. Analysis by Geographical Distribution
 
10.5. Neurostimulation Devices: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
 
11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Neurostimulation Devices: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Geographical Analysis by Number of Clinical Trials
11.3.3. Geographical Analysis by Enrolled Patient Population
11.3.4. Analysis by Trial Recruitment Status
11.3.5. Analysis by Type of Sponsors / Collaborators
11.3.6. Most Active Players in terms of Number of Trials
11.3.7. Analysis by Focus Area of Trials
11.3.8. Leading Indications in terms of Number of Trials
 
12. COLLABORATIONS AND PARTNERSHIPS
12.1. Chapter Overview
12.2. Partnership Models
 
12.3. Neurostimulation Devices: Recent Collaborations and Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Type of Device
12.3.4. Most Active Players by Number of Partnerships
12.3.5. Analysis by Geographical Regions
12.3.5.1. Most Active Players
12.3.5.2. Intercontinental and Intracontinental Agreements
 
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Neurostimulation Devices: Funding and Investment Analysis
13.3.1. Analysis by Number of Funding Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
13.3.5. Most Active Players
13.3.6. Most Active Investors
13.4. Concluding Remarks
 
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Neurostimulation Devices Market
14.3.1. Global Neurostimulation Devices Market, 2018-2030 (By Value)
14.3.2. Global Neurostimulation Devices Market, 2018-2030 (By Volume)
 
14.4. Global Neurostimulation Devices Market: Distribution by Type of Device, Indication and Geography
14.4.1. Global SCS Devices Market, 2018-2030 (By Value)
14.4.1.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Value)
14.4.1.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Value)
14.4.1.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Value)
14.4.1.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Value)
14.4.1.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Value)
14.4.1.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Value)
14.4.1.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Value)
14.4.1.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Value)
14.4.1.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Value)
14.4.1.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Value)
14.4.1.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Value)
 
14.4.2. Global SCS Devices Market, 2018-2030 (By Volume)
14.4.2.1. Global SCS Devices Market for Chronic Pain, 2018-2030 (By Volume)
14.4.2.1.1. SCS Devices Market for Chronic Pain in the US, 2018-2030 (By Volume)
14.4.2.1.2. SCS Devices Market for Chronic Pain in Canada, 2018-2030 (By Volume)
14.4.2.1.3. SCS Devices Market for Chronic Pain in the UK, 2018-2030 (By Volume)
14.4.2.1.4. SCS Devices Market for Chronic Pain in Germany, 2018-2030 (By Volume)
14.4.2.1.5. SCS Devices Market for Chronic Pain in France, 2018-2030 (By Volume)
14.4.2.1.6. SCS Devices Market for Chronic Pain in Spain, 2018-2030 (By Volume)
14.4.2.1.7. SCS Devices Market for Chronic Pain in Italy, 2018-2030 (By Volume)
14.4.2.1.8. SCS Devices Market for Chronic Pain in Australia, 2018-2030 (By Volume)
14.4.2.1.9. SCS Devices Market for Chronic Pain in China, 2018-2030 (By Volume)
14.4.2.1.10. SCS Devices Market for Chronic Pain in Japan, 2018-2030 (By Volume)
 
14.4.3. Global DBS Devices Market, 2018-2030 (By Value)
14.4.3.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Value)
14.4.3.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Value)
14.4.3.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Value)
14.4.3.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Value)
14.4.3.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Value)
14.4.3.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Value)
14.4.3.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Value)
14.4.3.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Value)
14.4.3.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Value)
14.4.3.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Value)
14.4.3.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Value)
 
14.4.3.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Value)
14.4.3.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Value)
14.4.3.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Value)
14.4.3.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Value)
14.4.3.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Value)
14.4.3.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Value)
14.4.3.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Value)
14.4.3.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Value)
14.4.3.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Value)
14.4.3.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Value)
14.4.3.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Value)
 
14.4.3.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Value)
14.4.3.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Value)
14.4.3.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Value)
14.4.3.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Value)
14.4.3.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Value)
14.4.3.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Value)
14.4.3.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Value)
14.4.3.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Value)
14.4.3.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Value)
14.4.3.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Value)
14.4.3.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Value)
 
14.4.3.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Value)
14.4.3.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Value)
14.4.3.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Value)
14.4.3.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Value)
14.4.3.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Value)
14.4.3.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Value)
14.4.3.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Value)
14.4.3.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Value)
14.4.3.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Value)
14.4.3.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Value)
14.4.3.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Value)
 
14.4.4. Global DBS Devices Market, 2018-2030 (By Volume)
14.4.4.1. Global DBS Devices Market for Essential Tremor, 2018-2030 (By Volume)
14.4.4.1.1. DBS Devices Market for Essential Tremor in the US, 2018-2030 (By Volume)
14.4.4.1.2. DBS Devices Market for Essential Tremor in Canada, 2018-2030 (By Volume)
14.4.4.1.3. DBS Devices Market for Essential Tremor in the UK, 2018-2030 (By Volume)
14.4.4.1.4. DBS Devices Market for Essential Tremor in Germany, 2018-2030 (By Volume)
14.4.4.1.5. DBS Devices Market for Essential Tremor in France, 2018-2030 (By Volume)
14.4.4.1.6. DBS Devices Market for Essential Tremor in Spain, 2018-2030 (By Volume)
14.4.4.1.7. DBS Devices Market for Essential Tremor in Italy, 2018-2030 (By Volume)
14.4.4.1.8. DBS Devices Market for Essential Tremor in Australia, 2018-2030 (By Volume)
14.4.4.1.9. DBS Devices Market for Essential Tremor in China, 2018-2030 (By Volume)
14.4.4.1.10. DBS Devices Market for Essential Tremor in Japan, 2018-2030 (By Volume)
 
14.4.4.2. Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (By Volume)
14.4.4.2.1. DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (By Volume)
14.4.4.2.2. DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (By Volume)
14.4.4.2.3. DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (By Volume)
14.4.4.2.4. DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (By Volume)
14.4.4.2.5. DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (By Volume)
14.4.4.2.6. DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (By Volume)
14.4.4.2.7. DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (By Volume)
14.4.4.2.8. DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (By Volume)
14.4.4.2.9. DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (By Volume)
14.4.4.2.10. DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (By Volume)
 
14.4.4.3. Global DBS Devices Market for Dystonia, 2018-2030 (By Volume)
14.4.4.3.1. DBS Devices Market for Dystonia in the US, 2018-2030 (By Volume)
14.4.4.3.2. DBS Devices Market for Dystonia in Canada, 2018-2030 (By Volume)
14.4.4.3.3. DBS Devices Market for Dystonia in the UK, 2018-2030 (By Volume)
14.4.4.3.4. DBS Devices Market for Dystonia in Germany, 2018-2030 (By Volume)
14.4.4.3.5. DBS Devices Market for Dystonia in France, 2018-2030 (By Volume)
14.4.4.3.6. DBS Devices Market for Dystonia in Spain, 2018-2030 (By Volume)
14.4.4.3.7. DBS Devices Market for Dystonia in Italy, 2018-2030 (By Volume)
14.4.4.3.8. DBS Devices Market for Dystonia in Australia, 2018-2030 (By Volume)
14.4.4.3.9. DBS Devices Market for Dystonia in China, 2018-2030 (By Volume)
14.4.4.3.10. DBS Devices Market for Dystonia in Japan, 2018-2030 (By Volume)
 
14.4.4.4. Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (By Volume)
14.4.4.4.1. DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (By Volume)
14.4.4.4.2. DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (By Volume)
14.4.4.4.3. DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (By Volume)
14.4.4.4.4. DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (By Volume)
14.4.4.4.5. DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (By Volume)
14.4.4.4.6. DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (By Volume)
14.4.4.4.7. DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (By Volume)
14.4.4.4.8. DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (By Volume)
14.4.4.4.9. DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (By Volume)
14.4.4.4.10. DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (By Volume)
 
14.4.5. Global VNS Devices Market, 2018-2030 (By Value)
14.4.5.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Value)
14.4.5.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Value)
14.4.5.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Value)
14.4.5.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Value)
14.4.5.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Value)
14.4.5.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Value)
14.4.5.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Value)
14.4.5.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Value)
14.4.5.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Value)
14.4.5.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Value)
14.4.5.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Value)
 
14.4.5.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Value)
14.4.5.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Value)
14.4.5.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Value)
14.4.5.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Value)
14.4.5.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Value)
14.4.5.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Value)
14.4.5.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Value)
14.4.5.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Value)
14.4.5.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Value)
14.4.5.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Value)
14.4.5.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Value)
 
14.4.6. Global VNS Devices Market, 2018-2030 (By Volume)
14.4.6.1. Global VNS Devices Market for Epilepsy, 2018-2030 (By Volume)
14.4.6.1.1. VNS Devices Market for Epilepsy in the US, 2018-2030 (By Volume)
14.4.6.1.2. VNS Devices Market for Epilepsy in Canada, 2018-2030 (By Volume)
14.4.6.1.3. VNS Devices Market for Epilepsy in the UK, 2018-2030 (By Volume)
14.4.6.1.4. VNS Devices Market for Epilepsy in Germany, 2018-2030 (By Volume)
14.4.6.1.5. VNS Devices Market for Epilepsy in France, 2018-2030 (By Volume)
14.4.6.1.6. VNS Devices Market for Epilepsy in Spain, 2018-2030 (By Volume)
14.4.6.1.7. VNS Devices Market for Epilepsy in Italy, 2018-2030 (By Volume)
14.4.6.1.8. VNS Devices Market for Epilepsy in Australia, 2018-2030 (By Volume)
14.4.6.1.9. VNS Devices Market for Epilepsy in China, 2018-2030 (By Volume)
14.4.6.1.10. VNS Devices Market for Epilepsy in Japan, 2018-2030 (By Volume)
 
14.4.6.2. Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (By Volume)
14.4.6.2.1. VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (By Volume)
14.4.6.2.2. VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (By Volume)
14.4.6.2.3. VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (By Volume)
14.4.6.2.4. VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (By Volume)
14.4.6.2.5. VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (By Volume)
14.4.6.2.6. VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (By Volume)
14.4.6.2.7. VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (By Volume)
14.4.6.2.8. VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (By Volume)
14.4.6.2.9. VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (By Volume)
14.4.6.2.10. VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (By Volume)
 
14.4.7. Global Other Neurostimulation Devices Market, 2018-2030 (By Value)
14.4.7.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Value)
14.4.7.1.1. Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Value)
14.4.7.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Value)
14.4.7.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Value)
14.4.7.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Value)
14.4.7.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Value)
14.4.7.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Value)
14.4.7.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Value)
14.4.7.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Value)
14.4.7.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Value)
14.4.7.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Value)
 
14.4.7.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Value)
14.4.7.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Value)
14.4.7.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Value)
14.4.7.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Value)
14.4.7.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Value)
14.4.7.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Value)
14.4.7.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Value)
14.4.7.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Value)
14.4.7.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Value)
14.4.7.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Value)
14.4.7.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Value)
 
14.4.7.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Value)
14.4.7.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Value)
14.4.7.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Value)
14.4.7.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Value)
14.4.7.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Value)
14.4.7.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Value)
14.4.7.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Value)
14.4.7.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Value)
14.4.7.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Value)
14.4.7.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Value)
14.4.7.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Value)
 
14.4.8. Global Other Neurostimulation Devices Market, 2018-2030 (By Volume)
14.4.8.1. Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (By Volume)
14.4.8.1.1 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (By Volume)
14.4.8.1.2. Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (By Volume)
14.4.8.1.3. Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (By Volume)
14.4.8.1.4. Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (By Volume)
14.4.8.1.5. Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (By Volume)
14.4.8.1.6. Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (By Volume)
14.4.8.1.7. Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (By Volume)
14.4.8.1.8. Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (By Volume)
14.4.8.1.9. Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (By Volume)
14.4.8.1.10. Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (By Volume)
 
14.4.8.2. Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (By Volume)
14.4.8.2.1. Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (By Volume)
14.4.8.2.2. Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (By Volume)
14.4.8.2.3. Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (By Volume)
14.4.8.2.4. Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (By Volume)
14.4.8.2.5. Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (By Volume)
14.4.8.2.6. Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (By Volume)
14.4.8.2.7. Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (By Volume)
14.4.8.2.8. Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (By Volume)
14.4.8.2.9. Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (By Volume)
14.4.8.2.10. Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (By Volume)
 
14.4.8.3. Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (By Volume)
14.4.8.3.1. Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (By Volume)
14.4.8.3.2. Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (By Volume)
14.4.8.3.3. Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (By Volume)
14.4.8.3.4. Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (By Volume)
14.4.8.3.5. Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (By Volume)
14.4.8.3.6. Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (By Volume)
14.4.8.3.7. Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (By Volume)
14.4.8.3.8. Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (By Volume)
14.4.8.3.9. Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (By Volume)
14.4.8.3.10. Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (By Volume)
 
14.5. Global Neurostimulation Devices Market: Distribution by MRI Compatibility
14.5.1. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Value)
14.5.2. Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
14.5.3. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Value)
14.5.4. Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (By Volume)
 
15. FUTURE GROWTH OPPORTUNITIES
15.1. Chapter Overview
15.2. Development of Devices to Address the Needs of Unexplored Therapeutic Areas
15.3. Integration of Novel and Advanced Features in Devices
15.4. Launch / Commercialization of Devices Across Different Geographies
15.5. Increased Utilization of Real World Data Based Insights to Optimize Device Performance and Support Regulatory / Reimbursement Decisions
15.6. Implementation of Cybersecurity Measures to Tackle Device Hacks
 
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. NeuroOne Medical Technologies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Dave Rosa, President and Chief Executive Officer
 
16.3. ReShape Lifesciences
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Deborah Schmalz, Vice President, Regulatory Affairs, Clinical Research and Compliances, and Diane Utzman-O'Neill, Vice President, Marketing
 
16.4. Mainstay Medical
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Jan Pieter Heemels, Vice President, Commercial Operations
 
16.5. Stimwave
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Laura Tyler Perryman, Chief Executive Officer
 
16.6. WISE
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Luca Ravagnan, Chief Executive Officer
 
16.7. Cardionomic
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Steve Goedeke, President and Chief Executive Officer
 
17. APPENDIX 1: LIST OF NON-INVASIVE NEUROSTIMULATION DEVICES
 
18. APPENDIX 2: TABULATED DATA
 
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

 

List of Figures

Figure 3.1 Common Types of Neurological Disorders
Figure 3.2 DALYs and Deaths from Selected Neurological Disorders, 2015
Figure 3.3 Conventional Treatment Methods for Neurological Disorders
Figure 3.4 Historical Evolution of Neurostimulation Devices
Figure 3.5 Types of Neurostimulation Devices
Figure 3.6 Applications of Neurostimulation Devices
Figure 3.7 Growth Drivers and Roadblocks Related to Neurostimulation Devices
Figure 3.8 Neurostimulation Devices: Social Media Trends
Figure 4.1. US FDA: Review / Approval Process
Figure 4.2. Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Figure 4.3. National Coverage Determination Process in the US
Figure 4.4. Health Canada: Review / Approval Process
Figure 4.5. Health Insurance Coverage in Canada: Distribution by Type of Coverage
Figure 4.6. Summary of CE Marking Process
Figure 4.7. Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Figure 4.8. Reimbursement Process in the UK
Figure 4.9. Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Figure 4.10. Reimbursement Process for In-patient Setting in Germany
Figure 4.11. Reimbursement Process for Out-patient Setting in Germany
Figure 4.12. Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Figure 4.13. Reimbursement Process of Medical Devices Through LPPR
Figure 4.14. Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Figure 4.15. Reimbursement Process of Medical Devices in Spain
Figure 4.16. Healthcare Insurance Coverage in Italy: Distribution by Type of Funding Sources
Figure 4.17. Reimbursement Process of Medical Devices in Italy
Figure 4.18. TGA: Review / Approval Process
Figure 4.19. Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Figure 4.20. CFDA: Review / Approval Process
Figure 4.21. Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Figure 4.22. Shanghai Reimbursement Approval Process
Figure 4.23. PMDA: Review / Approval Process
Figure 4.24. Snapshot of the Regulatory and Reimbursement Process in Japan
Figure 4.25. Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Figure 4.26. Reimbursement Process of New Medical Devices in Japan
Figure 4.27. Bubble Analysis: Regional Regulatory Control Comparison
Figure 5.1 Neurostimulation Devices: Recent Activities
Figure 5.2 Neurostimulation Devices: Distribution of Industry Players by Year of Establishment
Figure 5.3 Neurostimulation Devices: Distribution of Industry Players by Geographical Location
Figure 5.4 Neurostimulation Devices: Distribution of Industry Players by Size (Employee Count)
Figure 5.5 Neurostimulation Devices: Leading Developers in terms of Number of Devices
Figure 5.6 Neurostimulation Devices: Distribution by Type of Devices
Figure 5.7 Neurostimulation Devices: Distribution by Type of Target Nerves
Figure 5.8 Neurostimulation Devices: Leading Target Indications in terms of Number of Devices
Figure 5.9 Neurostimulation Devices: Distribution by Type of Regulatory Approval
Figure 5.10 Neurostimulation Devices, Grid Analysis: Distribution by Device Approval Year, Target Therapeutic Area and Type of Device
Figure 5.11 Neurostimulation Devices: Distribution by Size
Figure 5.12 Neurostimulation Devices: Distribution by Weight
Figure 5.13 Neurostimulation Devices: Distribution by Battery Type
Figure 5.14 Neurostimulation Devices: Distribution by Battery Longevity
Figure 5.15 Neurostimulation Devices: Distribution by Number of Electrodes
Figure 5.16 Neurostimulation Devices: Distribution by MRI Compatibility
Figure 6.1. SCS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 6.2. Medtronic: Net Sales, FY 2014-FY 2018 (USD Billion)
Figure 6.3. Medtronic, Net Sales: Distribution by Business Segments, FY 2018 (USD Billion)
Figure 6.4. Medtronic, Net Sales: Distribution by Region, FY 2018 (USD Billion)
Figure 6.5. Boston Scientific: Net Sales, FY 2013-H1 FY 2018 (USD Billion)
Figure 6.6. Boston Scientific, Net Sales: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 6.7. Boston Scientific, Net Sales: Distribution by Region, FY 2017 (USD Billion)
Figure 6.8. Nevro: Revenues, FY 2013-Q1 FY 2018 (USD Million)
Figure 6.9. Nevro, Revenues: Distribution by Region, FY 2017 (USD Million)
Figure 7.1. DBS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 7.2. Abbott: Net Sales, FY 2013-H1 FY 2018 (USD Billion)
Figure 7.3. Abbott, Net Sales: Distribution by Business Segments, FY 2017 (USD Billion)
Figure 7.4. Abbott, Net Sales: Distribution by Regions, FY 2017 (USD Billion)
Figure 8.1. SNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.2. VNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 8.3. LivaNova: Revenues, FY 2015-Q1 FY 2018 (USD Million)
Figure 8.4. LivaNova, Revenues: Distribution by Business Segments, FY 2017 (USD Million)
Figure 8.5. LivaNova, Revenues: Distribution by Regions, FY 2017 (USD Million)
Figure 8.6. Other CNS Devices Competitiveness Analysis: Dot-Plot Representation
Figure 9.1  Brand Positioning Analysis of Key Industry Players
Figure 9.2  Brand Positioning Matrix: Abbott (St. Jude Medical) 
Figure 9.3  Brand Positioning Matrix: Boston Scientific 
Figure 9.4  Brand Positioning Matrix: LivaNova
Figure 9.5  Brand Positioning Matrix: Medtronic 
Figure 9.6  Brand Positioning Matrix: Stimwave 
Figure 10.1 Patents: Distribution by Type
Figure 10.2 Patents: Cumulative Trend by Publication Year
Figure 10.3 Patents: Distribution by Geographical Location
Figure 10.4 Patents: Distribution by CPC Classifications (Top 20)
Figure 10.5 Patents: Emerging Areas
Figure 10.6 Patents: Distribution by Leading Players
Figure 10.7 Boston Scientific and Medtronic: Benchmarking by Patent Characteristics
Figure 10.8 Other Leading Patent Assignees: Benchmarking by Patent Characteristics
Figure 10.9 Industry Players: Benchmarking by Number of Patents Published Across Different Geographies
Figure 10.10 Industry Players: Benchmarking by Number of International Patents
Figure 10.11 Patents: Distribution by Age (January 2010-June 2018)
Figure 10.12 Patent Valuation
Figure 11.1 Clinical Trials: Distribution by Trial Status
Figure 11.2 Clinical Trials: Distribution by Registration Year
Figure 11.3 Clinical Trials: Geographical Distribution by Number of Trials
Figure 11.4 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 11.5 Clinical Trials: Distribution by Registration Year and Recruitment Status
Figure 11.6 Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status
Figure 11.7 Clinical Trials: Distribution by Type of Sponsors / Collaborators
Figure 11.8 Clinical Trials: Most Active Industry Players in terms of Number of Trials Conducted
Figure 11.9 Clinical Trials: Most Active Non-Industry Players in terms of Number of Trials Conducted
Figure 11.10 Clinical Trials: Focus Areas
Figure 11.11 Clinical Trials: Leading Indications in terms of Number of Trials 
Figure 11.12 Clinical Trials: Year-wise Trend of Top Five Indications
Figure 12.1 Recent Partnerships: Cumulative Half Year-wise Trend (2015–H1 2018)
Figure 12.2 Recent Partnerships: Distribution by Type of Model 
Figure 12.3 Recent Partnerships: Distribution by Year of Partnership and Type of Model
Figure 12.4 Recent Partnerships: Distribution by Type of Device
Figure 12.5 Recent Partnerships: Distribution by Year of Partnership and Type of Device
Figure 12.6 Recent Partnerships: Most Active Players
Figure 12.7 Recent Partnerships: Regional Distribution and Most Active Players
Figure 12.8 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Figure 13.1 Funding Instances: Cumulative Half Year-wise trend, January 2015-June 2018
Figure 13.2 Funding Instances: Cumulative Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.3 Funding Instances: Distribution by Type of Funding, January 2015-June 2018
Figure 13.4 Funding Instances: Distribution by Amount Invested and Type of Funding, January 2015-June 2018 (USD Million)
Figure 13.5 Summary of Investments, January 2015-June 2018 (USD Million)
Figure 13.6 Funding Instances: Most Popular Device Types by Number of Instances, January 2015-June 2018
Figure 13.7 Funding Instances: Most Popular Device Types by Amount Invested, January 2015-June 2018 (USD Million)
Figure 13.8 Funding Instances: Distribution by Year of Investment and Type of Device, January 2015-June 2018 (USD Million)
Figure 13.9 Funding Instances: Most Active Players in terms of Number of Instances, January 2015-June 2018
Figure 13.10 Funding Instances: Most Active Players in terms of Amount Invested, January 2015-June 2018
Figure 13.11 Funding Instances: Most Active Investors in terms of Number of Instances, January 2015-June 2018
Figure 13.12 Funding Instances: Funding and Investment Summary
Figure 14.1 Global Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.2 Global Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.3 Global SCS Devices Market, 2018-2030 (USD Million)
Figure 14.4 Global SCS Devices Market for Chronic Pain, 2018-2030 (USD Million)
Figure 14.5 SCS Devices Market for Chronic Pain in the US, 2018-2030 (USD Million)
Figure 14.6 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (USD Million)
Figure 14.7 SCS Devices Market for Chronic Pain in the UK, 2018-2030 (USD Million)
Figure 14.8 SCS Devices Market for Chronic Pain in Germany, 2018-2030 (USD Million)
Figure 14.9 SCS Devices Market for Chronic Pain in France, 2018-2030 (USD Million)
Figure 14.10 SCS Devices Market for Chronic Pain in Spain, 2018-2030 (USD Million)
Figure 14.11 SCS Devices Market for Chronic Pain in Italy, 2018-2030 (USD Million)
Figure 14.12 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (USD Million)
Figure 14.13 SCS Devices Market for Chronic Pain in China, 2018-2030 (USD Million)
Figure 14.14 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (USD Million)
Figure 14.15 Global SCS Devices Market, 2018-2030 (Units, Volume)
Figure 14.16 Global SCS Devices Market for Chronic Pain, 2018-2030 (Units, Volume)
Figure 14.17 SCS Devices Market for Chronic Pain in the US, 2018-2030 (Units, Volume)
Figure 14.18 SCS Devices Market for Chronic Pain in Canada, 2018-2030 (Units, Volume)
Figure 14.19 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.20 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.21 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.22 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.23 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Figure 14.24 SCS Devices Market for Chronic Pain in Australia, 2018-2030 (Units, Volume)
Figure 14.25 SCS Devices Market for Chronic Pain in China, 2018-2030 (Units, Volume)
Figure 14.26 SCS Devices Market for Chronic Pain in Japan, 2018-2030 (Units, Volume)
Figure 14.27 Global DBS Devices Market, 2018-2030 (USD Million)
Figure 14.28 Global DBS Devices Market for Essential Tremor, 2018-2030 (USD Million)
Figure 14.29 DBS Devices Market for Essential Tremor in the US, 2018-2030 (USD Million)
Figure 14.30 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (USD Million)
Figure 14.31 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (USD Million)
Figure 14.32 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (USD Million)
Figure 14.33 DBS Devices Market for Essential Tremor in France, 2018-2030 (USD Million)
Figure 14.34 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (USD Million)
Figure 14.35 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (USD Million)
Figure 14.36 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (USD Million)
Figure 14.37 DBS Devices Market for Essential Tremor in China, 2018-2030 (USD Million)
Figure 14.38 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (USD Million)
Figure 14.39 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (USD Million)
Figure 14.40 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (USD Million)
Figure 14.41 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (USD Million)
Figure 14.42 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (USD Million)
Figure 14.43 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (USD Million)
Figure 14.44 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (USD Million)
Figure 14.45 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (USD Million)
Figure 14.46 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (USD Million)
Figure 14.47 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (USD Million)
Figure 14.48 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (USD Million)
Figure 14.49 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (USD Million)
Figure 14.50 Global DBS Devices Market for Dystonia, 2018-2030 (USD Million)
Figure 14.51 DBS Devices Market for Dystonia in the US, 2018-2030 (USD Million)
Figure 14.52 DBS Devices Market for Dystonia in Canada, 2018-2030 (USD Million)
Figure 14.53 DBS Devices Market for Dystonia in the UK, 2018-2030 (USD Million)
Figure 14.54 DBS Devices Market for Dystonia in Germany, 2018-2030 (USD Million)
Figure 14.55 DBS Devices Market for Dystonia in France, 2018-2030 (USD Million)
Figure 14.56 DBS Devices Market for Dystonia in Spain, 2018-2030 (USD Million)
Figure 14.57 DBS Devices Market for Dystonia in Italy, 2018-2030 (USD Million)
Figure 14.58 DBS Devices Market for Dystonia in Australia, 2018-2030 (USD Million)
Figure 14.59 DBS Devices Market for Dystonia in China, 2018-2030 (USD Million)
Figure 14.60 DBS Devices Market for Dystonia in Japan, 2018-2030 (USD Million)
Figure 14.61 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (USD Million)
Figure 14.62 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (USD Million)
Figure 14.63 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.64 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.65 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.66 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (USD Million)
Figure 14.67 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.68 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.69 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.70 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (USD Million)
Figure 14.71 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.72 Global DBS Devices Market, 2018-2030 (Units, Volume)
Figure 14.73 Global DBS Devices Market for Essential Tremor, 2018-2030 (Units, Volume)
Figure 14.74 DBS Devices Market for Essential Tremor in the US, 2018-2030 (Units, Volume)
Figure 14.75 DBS Devices Market for Essential Tremor in Canada, 2018-2030 (Units, Volume)
Figure 14.76 DBS Devices Market for Essential Tremor in the UK, 2018-2030 (Units, Volume)
Figure 14.77 DBS Devices Market for Essential Tremor in Germany, 2018-2030 (Units, Volume)
Figure 14.78 DBS Devices Market for Essential Tremor in France, 2018-2030 (Units, Volume)
Figure 14.79 DBS Devices Market for Essential Tremor in Spain, 2018-2030 (Units, Volume)
Figure 14.80 DBS Devices Market for Essential Tremor in Italy, 2018-2030 (Units, Volume)
Figure 14.81 DBS Devices Market for Essential Tremor in Australia, 2018-2030 (Units, Volume)
Figure 14.82 DBS Devices Market for Essential Tremor in China, 2018-2030 (Units, Volume)
Figure 14.83 DBS Devices Market for Essential Tremor in Japan, 2018-2030 (Units, Volume)
Figure 14.84 Global DBS Devices Market for Parkinson’s Disease, 2018-2030 (Units, Volume)
Figure 14.85 DBS Devices Market for Parkinson’s Disease in the US, 2018-2030 (Units, Volume)
Figure 14.86 DBS Devices Market for Parkinson’s Disease in Canada, 2018-2030 (Units, Volume)
Figure 14.87 DBS Devices Market for Parkinson’s Disease in the UK, 2018-2030 (Units, Volume)
Figure 14.88 DBS Devices Market for Parkinson’s Disease in Germany, 2018-2030 (Units, Volume)
Figure 14.89 DBS Devices Market for Parkinson’s Disease in France, 2018-2030 (Units, Volume)
Figure 14.90 DBS Devices Market for Parkinson’s Disease in Spain, 2018-2030 (Units, Volume)
Figure 14.91 DBS Devices Market for Parkinson’s Disease in Italy, 2018-2030 (Units, Volume)
Figure 14.92 DBS Devices Market for Parkinson’s Disease in Australia, 2018-2030 (Units, Volume)
Figure 14.93 DBS Devices Market for Parkinson’s Disease in China, 2018-2030 (Units, Volume)
Figure 14.94 DBS Devices Market for Parkinson’s Disease in Japan, 2018-2030 (Units, Volume)
Figure 14.95 Global DBS Devices Market for Dystonia, 2018-2030 (Units, Volume)
Figure 14.96 DBS Devices Market for Dystonia in the US, 2018-2030 (Units, Volume)
Figure 14.97 DBS Devices Market for Dystonia in Canada, 2018-2030 (Units, Volume)
Figure 14.98 DBS Devices Market for Dystonia in the UK, 2018-2030 (Units, Volume)
Figure 14.99 DBS Devices Market for Dystonia in Germany, 2018-2030 (Units, Volume)
Figure 14.100 DBS Devices Market for Dystonia in France, 2018-2030 (Units, Volume)
Figure 14.101 DBS Devices Market for Dystonia in Spain, 2018-2030 (Units, Volume)
Figure 14.102 DBS Devices Market for Dystonia in Italy, 2018-2030 (Units, Volume)
Figure 14.103 DBS Devices Market for Dystonia in Australia, 2018-2030 (Units, Volume)
Figure 14.104 DBS Devices Market for Dystonia in China, 2018-2030 (Units, Volume)
Figure 14.105 DBS Devices Market for Dystonia in Japan, 2018-2030 (Units, Volume)
Figure 14.106 Global DBS Devices Market for Obsessive Compulsive Disorder, 2018-2030 (Units, Volume)
Figure 14.107 DBS Devices Market for Obsessive Compulsive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.108 DBS Devices Market for Obsessive Compulsive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.109 DBS Devices Market for Obsessive Compulsive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.110 DBS Devices Market for Obsessive Compulsive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.111 DBS Devices Market for Obsessive Compulsive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.112 DBS Devices Market for Obsessive Compulsive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.113 DBS Devices Market for Obsessive Compulsive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.114 DBS Devices Market for Obsessive Compulsive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.115 DBS Devices Market for Obsessive Compulsive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.116 DBS Devices Market for Obsessive Compulsive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.117 Global VNS Devices Market, 2018-2030 (USD Million)
Figure 14.118 Global VNS Devices Market for Epilepsy, 2018-2030 (USD Million)
Figure 14.119 VNS Devices Market for Epilepsy in the US, 2018-2030 (USD Million)
Figure 14.120 VNS Devices Market for Epilepsy in Canada, 2018-2030 (USD Million)
Figure 14.121 VNS Devices Market for Epilepsy in the UK, 2018-2030 (USD Million)
Figure 14.122 VNS Devices Market for Epilepsy in Germany, 2018-2030 (USD Million)
Figure 14.123 VNS Devices Market for Epilepsy in France, 2018-2030 (USD Million)
Figure 14.124 VNS Devices Market for Epilepsy in Spain, 2018-2030 (USD Million)
Figure 14.125 VNS Devices Market for Epilepsy in Italy, 2018-2030 (USD Million)
Figure 14.126 VNS Devices Market for Epilepsy in Australia, 2018-2030 (USD Million)
Figure 14.127 VNS Devices Market for Epilepsy in China, 2018-2030 (USD Million)
Figure 14.128 VNS Devices Market for Epilepsy in Japan, 2018-2030 (USD Million)
Figure 14.129 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (USD Million)
Figure 14.130 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (USD Million)
Figure 14.131 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (USD Million)
Figure 14.132 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (USD Million)
Figure 14.133 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (USD Million)
Figure 14.134 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (USD Million)
Figure 14.135 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (USD Million)
Figure 14.136 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (USD Million)
Figure 14.137 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (USD Million)
Figure 14.138 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (USD Million)
Figure 14.139 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (USD Million)
Figure 14.140 Global VNS Devices Market, 2018-2030 (Units, Volume)
Figure 14.141 Global VNS Devices Market for Epilepsy, 2018-2030 (Units, Volume)
Figure 14.142 VNS Devices Market for Epilepsy in the US, 2018-2030 (Units, Volume)
Figure 14.143 VNS Devices Market for Epilepsy in Canada, 2018-2030 (Units, Volume)
Figure 14.144 VNS Devices Market for Epilepsy in the UK, 2018-2030 (Units, Volume)
Figure 14.145 VNS Devices Market for Epilepsy in Germany, 2018-2030 (Units, Volume)
Figure 14.146 VNS Devices Market for Epilepsy in France, 2018-2030 (Units, Volume)
Figure 14.147 VNS Devices Market for Epilepsy in Spain, 2018-2030 (Units, Volume)
Figure 14.148 VNS Devices Market for Epilepsy in Italy, 2018-2030 (Units, Volume)
Figure 14.149 VNS Devices Market for Epilepsy in Australia, 2018-2030 (Units, Volume)
Figure 14.150 VNS Devices Market for Epilepsy in China, 2018-2030 (Units, Volume)
Figure 14.151 VNS Devices Market for Epilepsy in Japan, 2018-2030 (Units, Volume)
Figure 14.152 Global VNS Devices Market for Major Depressive Disorder, 2018-2030 (Units, Volume)
Figure 14.153 VNS Devices Market for Major Depressive Disorder in the US, 2018-2030 (Units, Volume)
Figure 14.154 VNS Devices Market for Major Depressive Disorder in Canada, 2018-2030 (Units, Volume)
Figure 14.155 VNS Devices Market for Major Depressive Disorder in the UK, 2018-2030 (Units, Volume)
Figure 14.156 VNS Devices Market for Major Depressive Disorder in Germany, 2018-2030 (Units, Volume)
Figure 14.157 VNS Devices Market for Major Depressive Disorder in France, 2018-2030 (Units, Volume)
Figure 14.158 VNS Devices Market for Major Depressive Disorder in Spain, 2018-2030 (Units, Volume)
Figure 14.159 VNS Devices Market for Major Depressive Disorder in Italy, 2018-2030 (Units, Volume)
Figure 14.160 VNS Devices Market for Major Depressive Disorder in Australia, 2018-2030 (Units, Volume)
Figure 14.161 VNS Devices Market for Major Depressive Disorder in China, 2018-2030 (Units, Volume)
Figure 14.162 VNS Devices Market for Major Depressive Disorder in Japan, 2018-2030 (Units, Volume)
Figure 14.163 Global Other Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.164 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (USD Million)
Figure 14.165 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (USD Million)
Figure 14.166 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (USD Million)
Figure 14.167 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (USD Million)
Figure 14.168 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (USD Million)
Figure 14.169 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (USD Million)
Figure 14.170 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (USD Million)
Figure 14.171 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (USD Million)
Figure 14.172 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (USD Million)
Figure 14.173 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (USD Million)
Figure 14.174 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (USD Million)
Figure 14.175 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (USD Million)
Figure 14.176 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (USD Million)
Figure 14.177 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (USD Million)
Figure 14.178 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (USD Million)
Figure 14.179 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (USD Million)
Figure 14.180 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (USD Million)
Figure 14.181 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (USD Million)
Figure 14.182 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (USD Million)
Figure 14.183 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (USD Million)
Figure 14.184 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (USD Million)
Figure 14.185 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (USD Million)
Figure 14.186 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (USD Million)
Figure 14.187 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (USD Million)
Figure 14.188 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (USD Million)
Figure 14.189 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (USD Million)
Figure 14.190 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (USD Million)
Figure 14.191 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (USD Million)
Figure 14.192 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (USD Million)
Figure 14.193 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (USD Million)
Figure 14.194 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (USD Million)
Figure 14.195 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (USD Million)
Figure 14.196 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (USD Million)
Figure 14.197 Global Other Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.198 Global Other Neurostimulation Devices Market for Overactive Bladder, 2018-2030 (Units, Volume)
Figure 14.199 Other Neurostimulation Devices Market for Overactive Bladder in the US, 2018-2030 (Units, Volume)
Figure 14.200 Other Neurostimulation Devices Market for Overactive Bladder in Canada, 2018-2030 (Units, Volume)
Figure 14.201 Other Neurostimulation Devices Market for Overactive Bladder in the UK, 2018-2030 (Units, Volume)
Figure 14.202 Other Neurostimulation Devices Market for Overactive Bladder in Germany, 2018-2030 (Units, Volume)
Figure 14.203 Other Neurostimulation Devices Market for Overactive Bladder in France, 2018-2030 (Units, Volume)
Figure 14.204 Other Neurostimulation Devices Market for Overactive Bladder in Spain, 2018-2030 (Units, Volume)
Figure 14.205 Other Neurostimulation Devices Market for Overactive Bladder in Italy, 2018-2030 (Units, Volume)
Figure 14.206 Other Neurostimulation Devices Market for Overactive Bladder in Australia, 2018-2030 (Units, Volume)
Figure 14.207 Other Neurostimulation Devices Market for Overactive Bladder in China, 2018-2030 (Units, Volume)
Figure 14.208 Other Neurostimulation Devices Market for Overactive Bladder in Japan, 2018-2030 (Units, Volume)
Figure 14.209 Global Other Neurostimulation Devices Market for Heart Failure, 2018-2030 (Units, Volume)
Figure 14.210 Other Neurostimulation Devices Market for Heart Failure in the US, 2018-2030 (Units, Volume)
Figure 14.211 Other Neurostimulation Devices Market for Heart Failure in Canada, 2018-2030 (Units, Volume)
Figure 14.212 Other Neurostimulation Devices Market for Heart Failure in the UK, 2018-2030 (Units, Volume)
Figure 14.213 Other Neurostimulation Devices Market for Heart Failure in Germany, 2018-2030 (Units, Volume)
Figure 14.214 Other Neurostimulation Devices Market for Heart Failure in France, 2018-2030 (Units, Volume)
Figure 14.215 Other Neurostimulation Devices Market for Heart Failure in Spain, 2018-2030 (Units, Volume)
Figure 14.216 Other Neurostimulation Devices Market for Heart Failure in Italy, 2018-2030 (Units, Volume)
Figure 14.217 Other Neurostimulation Devices Market for Heart Failure in Australia, 2018-2030 (Units, Volume)
Figure 14.218 Other Neurostimulation Devices Market for Heart Failure in China, 2018-2030 (Units, Volume)
Figure 14.219 Other Neurostimulation Devices Market for Heart Failure in Japan, 2018-2030 (Units, Volume)
Figure 14.220 Global Other Neurostimulation Devices Market for Sleep Apnea, 2018-2030 (Units, Volume)
Figure 14.221 Other Neurostimulation Devices Market for Sleep Apnea in the US, 2018-2030 (Units, Volume)
Figure 14.222 Other Neurostimulation Devices Market for Sleep Apnea in Canada, 2018-2030 (Units, Volume)
Figure 14.223 Other Neurostimulation Devices Market for Sleep Apnea in the UK, 2018-2030 (Units, Volume)
Figure 14.224 Other Neurostimulation Devices Market for Sleep Apnea in Germany, 2018-2030 (Units, Volume)
Figure 14.225 Other Neurostimulation Devices Market for Sleep Apnea in France, 2018-2030 (Units, Volume)
Figure 14.226 Other Neurostimulation Devices Market for Sleep Apnea in Spain, 2018-2030 (Units, Volume)
Figure 14.227 Other Neurostimulation Devices Market for Sleep Apnea in Italy, 2018-2030 (Units, Volume)
Figure 14.228 Other Neurostimulation Devices Market for Sleep Apnea in Australia, 2018-2030 (Units, Volume)
Figure 14.229 Other Neurostimulation Devices Market for Sleep Apnea in China, 2018-2030 (Units, Volume)
Figure 14.230 Other Neurostimulation Devices Market for Sleep Apnea in Japan, 2018-2030 (Units, Volume)
Figure 14.231 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.232 Global MRI Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)
Figure 14.233 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (USD Million)
Figure 14.234 Global MRI Non-Compatible Neurostimulation Devices Market, 2018-2030 (Units, Volume)

List of Tables

Table 3.1 Basic Components of Neurostimulation Devices
Table 3.2 Comparison of Different Types of Neurostimulation Devices
Table 4.1 General Guidelines for Market Authorization and Reimbursement for Medical Devices
Table 4.2 Device Classification: US
Table 4.3 Device Classification: Canada
Table 4.4 Data Requirements and Characteristics of Province-wise HTA Processes in Canada
Table 4.5 Regulatory Bodies in EU5 Countries
Table 4.6 Device Classification: Europe
Table 4.7 List of CE Directives in Europe
Table 4.8 Conformity Assessment Modules in Europe
Table 4.9 Device Classification: Australia
Table 4.10 Reimbursement and Pricing Approval Process of Medical Devices in Australia
Table 4.11 Device Classification: China
Table 4.12 Device Classification: Europe
Table 4.13 Medical Device Reimbursement Categories
Table 4.14 Medical Devices: Regulatory and Reimbursement Landscape Summary
Table 5.1 List of Neurostimulation Devices
Table 5.2 List of Neurostimulation Devices: Information on Therapeutic Areas and Development / Approval Status
Table 5.3 Neurostimulation Devices, Heat Map: Distribution by Target Therapeutic Area and Type of Device
Table 5.4 List of Neurostimulation Devices: Information on Key Device Specifications
Table 5.5 List of Additional Neurostimulation Devices
Table 6.1 SCS Devices Competitiveness Analysis: Final Output
Table 6.2 Medtronic: Key Highlights
Table 6.3 Medtronic: Key Characteristics of Intellis™
Table 6.4 Medtronic: Recent Developments and Future Outlook
Table 6.5 Boston Scientific: Key Highlights
Table 6.6 Boston Scientific: Key Characteristics of Precision™ Plus
Table 6.7 Boston Scientific: Recent Developments and Future Outlook
Table 6.8 Stimwave: Key Highlights 
Table 6.9 Stimwave: Key Characteristics of Senza®
Table 6.10 Stimwave: Recent Developments and Future Outlook
Table 6.11 Nevro: Key Highlights
Table 6.12 Nevro: Key Characteristics of Senza®
Table 6.13 Nevro: Recent Developments and Future Outlook
Table 7.1 DBS Devices Competitiveness Analysis: Final Output
Table 7.2 Medtronic: Key Characteristics of Activa™ PC, Activa™ SC, Activa™ RC
Table 7.3 Medtronic: Recent Developments and Future Outlook
Table 7.4 Boston Scientific: Key Characteristics of Vercise™ DBS, Vercise Gevia™
Table 7.5 Boston Scientific: Recent Developments and Future Outlook
Table 7.6 Beijing PINS Medical: Key Highlights
Table 7.7 Beijing PINS Medical: Key Characteristics of PINS™ DBS System
Table 7.8 Beijing PINS Medical: Recent Developments and Future Outlook
Table 7.9 Abbott (St. Jude Medical): Key Highlights
Table 7.10 Abbott (St. Jude Medical): Key Characteristics of Brio™
Table 7.11 Abbott (St. Jude Medical): Recent Developments and Future Outlook
Table 8.1 SNS Devices Competitiveness Analysis: Final Output
Table 8.2 Axonics Modulation Technologies: Key Highlights
Table 8.3 Axonics Modulation Technologies: Key Characteristics of Axonics® r-SNM™ System
Table 8.4 Axonics Modulation Technologies: Recent Developments and Future Outlook
Table 8.5 BrainsGate: Key Highlights
Table 8.6 BrainsGate: Key Characteristics of Ischemic Stroke System™
Table 8.7 BrainsGate: Recent Developments and Future Outlook
Table 8.8 Medtronic: Key Characteristics of InterStim II
Table 8.9 VNS Devices Competitiveness Analysis: Final Output
Table 8.10 LivaNova: Key Highlights
Table 8.11 LivaNova: Key Characteristics of Pulse, Pulse Duo, AspireHC®, AspireSR®, SenTiva®
Table 8.12 LivaNova: Recent Developments and Future Outlook
Table 8.13 SetPoint Medical: Key Highlights
Table 8.14 SetPoint Medical: Key Characteristics of Unnamed Bioelectronic Platform
Table 8.15 Setpoint Medical: Recent Developments and Future Outlook
Table 8.16 Synergia Medical: Key Highlights
Table 8.17 Synergia Medical: Key Characteristics of NAOS Platform
Table 8.18 Synergia Medical: Recent Developments and Future Outlook
Table 8.19 Other CNS Devices Competitiveness Analysis: Final Output
Table 8.20 Bioness: Key Highlights
Table 8.21 Bioness: Key Characteristics of StimRouter®
Table 8.22 Bioness: Recent Developments and Future Outlook
Table 8.23 Nyxoah: Key Highlights
Table 8.24 Nyxoah: Funding Instances
Table 8.25 Nyxoah: Key Characteristics of Genio™
Table 8.26 Nyxoah: Recent Developments and Future Outlook
Table 8.27 BlueWind Medical: Key Highlights
Table 8.28 BlueWind Medical: Key Characteristics of RENOVA™, VIVENDI™
Table 8.29 BlueWind Medical: Recent Developments and Future Outlook
Table 10.1 Patents: CPC Classification Symbol Definitions
Table 10.2 Patents: Most Popular CPC Classification Symbols
Table 10.3 Patents: List of Top CPC Classifications
Table 10.4 Patents: List of Leading Individual Assignees
Table 10.5 Patents: Summary of Benchmarking Analysis
Table 10.6 Patent Valuation Analysis: Categorization based on Weighted Scores
Table 10.7 Patents: List of Leading Patents (by Highest Relative Valuation) 
Table 10.8 Patents: List of Leading Patents (by Number of Citations)
Table 12.1 Neurostimulation Devices: List of Partnerships
Table 12.2 Recent Partnerships: Most Active Players
Table 13.1 Neurostimulation Devices: Funding and Investments, January 2015-June 2018
Table 13.2 Neurostimulation Devices: Summary of Investments
Table 16.1 NeuroOne Medical Technologies: Key Highlights
Table 16.2 ReShape Lifesciences: Key Highlights
Table 16.3 Mainstay Medical: Key Highlights
Table 16.4 Stimwave: Key Highlights
Table 16.5 WISE: Key Highlights
Table 16.6 Cardionomic: Key Highlights
Table 17.1 List of Non-invasive Neurostimulation Devices
Table 18.1 DALYs and Deaths from Selected Neurological Disorders, 2015
Table 18.2 Healthcare Insurance Coverage in the US: Distribution by Type of Coverage
Table 18.3 Healthcare Insurance Coverage in Canada: Distribution by Type of Coverage
Table 18.4 Healthcare Insurance Coverage in the UK: Distribution by Type of Coverage
Table 18.5 Healthcare Insurance Coverage in Germany: Distribution by Type of Coverage
Table 18.6 Healthcare Insurance Coverage in France: Distribution by Type of Coverage
Table 18.7 Healthcare Insurance Coverage in Spain: Distribution by Type of Coverage
Table 18.8 Healthcare Insurance Coverage in Italy: Distribution by Type of Coverage
Table 18.9 Healthcare Insurance Coverage in Australia: Distribution by Type of Coverage
Table 18.10 Healthcare Insurance Coverage in China: Distribution by Type of Coverage
Table 18.11 Healthcare Insurance Coverage in Japan: Distribution by Type of Coverage
Table 18.12 Neurostimulation Devices: Distribution of Industry Players by Year of Establishment
Table 18.13 Neurostimulation Devices: Distribution of Industry Players by Geographical Location
Table 18.14 Neurostimulation Devices: Distribution of Industry Players by Size (Employee Count)
Table 18.15 Neurostimulation Devices: Leading Developers in Terms of Number of Devices
Table 18.16 Neurostimulation Devices: Distribution by Types of Devices
Table 18.17 Neurostimulation Devices: Distribution by Types of Target Nerves
Table 18.18 Neurostimulation Devices: Leading Target Indications in Terms of Number of Devices
Table 18.19 Neurostimulation Devices: Distribution by Types of Regulatory Approvals
Table 18.20 Neurostimulation Devices: Distribution by Size
Table 18.21 Neurostimulation Devices: Distribution by Weight
Table 18.22 Neurostimulation Devices: Distribution by Battery Type
Table 18.23 Neurostimulation Devices: Distribution by Battery Longevity
Table 18.24 Neurostimulation Devices: Distribution by Number of Electrodes
Table 18.25 Neurostimulation Devices: Distribution by MRI Compatibility
Table 18.26 Medtronic: Revenues, FY 2014-FY 2018 (USD Billion)
Table 18.27 Medtronic, Revenues: Distribution by Business Segments, FY 2018 (USD Billion)
Table 18.28 Medtronic, Revenues: Distribution by Regions, FY 2018 (USD Billion)
Table 18.29 Boston Scientific: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Table 18.30 Boston Scientific, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Table 18.31 Boston Scientific, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Table 18.32 Nevro: Revenues, FY 2013-Q1 FY 2018 (USD Million)
Table 18.33 Nevro, Revenues: Distribution by Regions, FY 2017 (USD Million)
Table 18.34 Abbott: Revenues, FY 2013-H1 FY 2018 (USD Billion)
Table 18.35 Abbott, Revenues: Distribution by Business Segments, FY 2017 (USD Billion)
Table 18.36 Abbott, Revenues: Distribution by Regions, FY 2017 (USD Billion)
Table 18.37 LivaNova: Revenues, FY 2015-Q1 FY 2018 (USD Million)
Table 18.38 LivaNova, Revenues: Distribution by Business Segments, FY 2017 (USD Million)
Table 18.39 LivaNova, Revenues: Distribution by Regions, FY 2017 (USD Million)
Table 18.40 Patents: Distribution by Type
Table 18.41 Patents: Cumulative Trend by Publication Year
Table 18.42 Patents: Distribution by Geographical Location
Table 18.43 Patents: Distribution by Leading Players
Table 18.44 Boston Scientific and Medtronic: Benchmarking by Patent Characteristics
Table 18.45 Other Leading Patent Assignees: Benchmarking by Patent Characteristics
Table 18.46 Industry Players: Benchmarking by Number of Patents Published Across Different Geographies
Table 18.47 Industry Players: Benchmarking by Number of International Patents
Table 18.48 Patents: Distribution by Age (January 2010-June 2018)
Table 18.49 Patent Valuation
Table 18.50 Clinical Trials: Distribution by Trial Status
Table 18.51 Clinical Trials: Distribution by Registration Year
Table 18.52 Clinical Trials: Geographical Distribution by Number of Trials
Table 18.53 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Table 18.54 Clinical Trials: Year-wise Trend of Trial Recruitment Status
Table 18.55 Clinical Trials: Geographical Distribution by Registration Year and Recruitment Status
Table 18.56 Clinical Trials: Distribution by Type of Sponsors / Collaborators
Table 18.57 Clinical Trials: Most Active Industry Players in Terms of Number of Trials Conducted
Table 18.58 Clinical Trials: Most Active Non-Industry Players in Terms of Number of Trials Conducted
Table 18.59 Clinical Trials: Leading Indications in Terms of Number of Trials
Table 18.60 Clinical Trials: Year-wise Trend of Top Five Indications
Table 18.61 Recent Partnerships: Cumulative Half Year-wise Trend (2015–H1 2018)
Table 18.62 Recent Partnerships: Distribution by Type of Model 
Table 18.63 Recent Partnerships: Distribution by Year of Partnership and Type of Model
Table 18.64 Recent Partnerships: Distribution by Type of Device
Table 18.65 Recent Partnerships: Distribution by Year of Partnership and Type of Device
Table 18.66 Recent Partnerships: Most Active Players
Table 18.67 Recent Partnerships: Regional Distribution and Most Active Players
Table 18.68 Recent Partnerships: Regional Distribution by Intercontinental and Intracontinental Agreements
Table 18.69 Funding Instances: Cumulative Half Year-wise trend, January 2015-June 2018
Table 18.70 Funding Instances: Cumulative Amount Invested, January 2015-June 2018 (USD Million)
Table 18.71 Funding Instances: Distribution by Type of Funding, January 2015-June 2018
Table 18.72 Funding Instances: Distribution by Amount Invested and Type of Funding, January 2015-June 2018 (USD Million)
Table 18.73 Summary of Investments, January 2015-June 2018 (USD Million)
Table 18.74 Funding Instances: Most Popular Device Types by Number of Instances, January 2015-June 2018
Table 18.75 Funding Instances: Most Popular Device Types by Amount Invested, January 2015-June 2018 (USD Million)
Table 18.76 Funding Instances: Distribution by Year of Investment and Type of Device, January 2015-June 2018 (USD Million)
Table 18.77 Funding Instances: Most Active Players in Terms of Number of Instances, January 2015-June 2018
Table 18.78 Funding Instances: Most Active Players in Terms of Amount Invested, January 2015-June 2018
Table 18.79 Funding Instances: Most Active Investors in Terms of Number of Instances, January 2015-June 2018
Table 18.80 Funding Instances: Funding and Investment Summary
Table 18.81 Global Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.82 Global Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.83 Global SCS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.84 Global SCS Devices Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.85 SCS Devices Market for Chronic Pain in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.86 SCS Devices Market for Chronic Pain in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.87 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.88 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.89 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.90 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.91 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.92 SCS Devices Market for Chronic Pain in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.93 SCS Devices Market for Chronic Pain in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.94 SCS Devices Market for Chronic Pain in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.95 Global SCS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.96 Global SCS Devices Market for Chronic Pain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.97 SCS Devices Market for Chronic Pain in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.98 SCS Devices Market for Chronic Pain in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.99 SCS Devices Market for Chronic Pain in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.100 SCS Devices Market for Chronic Pain in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.101 SCS Devices Market for Chronic Pain in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.102 SCS Devices Market for Chronic Pain in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.103 SCS Devices Market for Chronic Pain in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.104 SCS Devices Market for Chronic Pain in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.105 SCS Devices Market for Chronic Pain in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.107 SCS Devices Market for Chronic Pain in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.108 Global DBS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.109 Global DBS Devices Market for Essential Tremor, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.110 DBS Devices Market for Essential Tremor in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.111 DBS Devices Market for Essential Tremor in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.112 DBS Devices Market for Essential Tremor in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.113 DBS Devices Market for Essential Tremor in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.114 DBS Devices Market for Essential Tremor in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.115 DBS Devices Market for Essential Tremor in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.116 DBS Devices Market for Essential Tremor in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.117 DBS Devices Market for Essential Tremor in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.118 DBS Devices Market for Essential Tremor in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.119 DBS Devices Market for Essential Tremor in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.120 Global DBS Devices Market for Parkinson’s Disease, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.121 DBS Devices Market for Parkinson’s Disease in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.122 DBS Devices Market for Parkinson’s Disease in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.123 DBS Devices Market for Parkinson’s Disease in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.124 DBS Devices Market for Parkinson’s Disease in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.125 DBS Devices Market for Parkinson’s Disease in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.126 DBS Devices Market for Parkinson’s Disease in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.127 DBS Devices Market for Parkinson’s Disease in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.128 DBS Devices Market for Parkinson’s Disease in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.129 DBS Devices Market for Parkinson’s Disease in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.130 DBS Devices Market for Parkinson’s Disease in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.131 Global DBS Devices Market for Dystonia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.132 DBS Devices Market for Dystonia in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.133 DBS Devices Market for Dystonia in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.134 DBS Devices Market for Dystonia in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.135 DBS Devices Market for Dystonia in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.136 DBS Devices Market for Dystonia in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.137 DBS Devices Market for Dystonia in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.138 DBS Devices Market for Dystonia in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.139 DBS Devices Market for Dystonia in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.140 DBS Devices Market for Dystonia in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.141 DBS Devices Market for Dystonia in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.142 Global DBS Devices Market for Obsessive Compulsive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.143 DBS Devices Market for Obsessive Compulsive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.144 DBS Devices Market for Obsessive Compulsive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.145 DBS Devices Market for Obsessive Compulsive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.146 DBS Devices Market for Obsessive Compulsive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.147 DBS Devices Market for Obsessive Compulsive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.148 DBS Devices Market for Obsessive Compulsive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.149 DBS Devices Market for Obsessive Compulsive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.150 DBS Devices Market for Obsessive Compulsive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.151 DBS Devices Market for Obsessive Compulsive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.152 DBS Devices Market for Obsessive Compulsive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.153 Global DBS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.154 Global DBS Devices Market for Essential Tremor, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.155 DBS Devices Market for Essential Tremor in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.156 DBS Devices Market for Essential Tremor in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.157 DBS Devices Market for Essential Tremor in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.158 DBS Devices Market for Essential Tremor in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.159 DBS Devices Market for Essential Tremor in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.160 DBS Devices Market for Essential Tremor in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.161 DBS Devices Market for Essential Tremor in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.162 DBS Devices Market for Essential Tremor in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.163 DBS Devices Market for Essential Tremor in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.164 DBS Devices Market for Essential Tremor in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.165 Global DBS Devices Market for Parkinson’s Disease, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.166 DBS Devices Market for Parkinson’s Disease in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.167 DBS Devices Market for Parkinson’s Disease in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.168 DBS Devices Market for Parkinson’s Disease in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.169 DBS Devices Market for Parkinson’s Disease in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.170 DBS Devices Market for Parkinson’s Disease in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.171 DBS Devices Market for Parkinson’s Disease in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.172 DBS Devices Market for Parkinson’s Disease in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.173 DBS Devices Market for Parkinson’s Disease in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.174 DBS Devices Market for Parkinson’s Disease in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.175 DBS Devices Market for Parkinson’s Disease in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.176 Global DBS Devices Market for Dystonia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.177 DBS Devices Market for Dystonia in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.178 DBS Devices Market for Dystonia in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.179 DBS Devices Market for Dystonia in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.180 DBS Devices Market for Dystonia in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.181 DBS Devices Market for Dystonia in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.182 DBS Devices Market for Dystonia in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.183 DBS Devices Market for Dystonia in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.184 DBS Devices Market for Dystonia in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.185 DBS Devices Market for Dystonia in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.186 DBS Devices Market for Dystonia in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.187 Global DBS Devices Market for Obsessive Compulsive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.188 DBS Devices Market for Obsessive Compulsive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.189 DBS Devices Market for Obsessive Compulsive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.190 DBS Devices Market for Obsessive Compulsive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.191 DBS Devices Market for Obsessive Compulsive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.192 DBS Devices Market for Obsessive Compulsive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.193 DBS Devices Market for Obsessive Compulsive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.194 DBS Devices Market for Obsessive Compulsive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.195 DBS Devices Market for Obsessive Compulsive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.196 DBS Devices Market for Obsessive Compulsive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.197 DBS Devices Market for Obsessive Compulsive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.198 Global VNS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.199 Global VNS Devices Market for Epilepsy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.200 VNS Devices Market for Epilepsy in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.201 VNS Devices Market for Epilepsy in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.202 VNS Devices Market for Epilepsy in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.203 VNS Devices Market for Epilepsy in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.204 VNS Devices Market for Epilepsy in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.205 VNS Devices Market for Epilepsy in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.206 VNS Devices Market for Epilepsy in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.207 VNS Devices Market for Epilepsy in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.208 VNS Devices Market for Epilepsy in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.209 VNS Devices Market for Epilepsy in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.210 Global VNS Devices Market for Major Depressive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.211 VNS Devices Market for Major Depressive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.212 VNS Devices Market for Major Depressive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.213 VNS Devices Market for Major Depressive Disorder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.214 VNS Devices Market for Major Depressive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.215 VNS Devices Market for Major Depressive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.216 VNS Devices Market for Major Depressive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.217 VNS Devices Market for Major Depressive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.218 VNS Devices Market for Major Depressive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.219 VNS Devices Market for Major Depressive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.220 VNS Devices Market for Major Depressive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.221 Global VNS Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.222 Global VNS Devices Market for Epilepsy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.223 VNS Devices Market for Epilepsy in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.224 VNS Devices Market for Epilepsy in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.225 VNS Devices Market for Epilepsy in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.226 VNS Devices Market for Epilepsy in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.227 VNS Devices Market for Epilepsy in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.228 VNS Devices Market for Epilepsy in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.229 VNS Devices Market for Epilepsy in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.230 VNS Devices Market for Epilepsy in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.231 VNS Devices Market for Epilepsy in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.232 VNS Devices Market for Epilepsy in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.233 Global VNS Devices Market for Major Depressive Disorder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.234 VNS Devices Market for Major Depressive Disorder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.235 VNS Devices Market for Major Depressive Disorder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.236 VNS Devices Market for Major Depressive Disorder in the UK, Conservative, Base an8d Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.237 VNS Devices Market for Major Depressive Disorder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.238 VNS Devices Market for Major Depressive Disorder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.239 VNS Devices Market for Major Depressive Disorder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.240 VNS Devices Market for Major Depressive Disorder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.241 VNS Devices Market for Major Depressive Disorder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.242 VNS Devices Market for Major Depressive Disorder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.243 VNS Devices Market for Major Depressive Disorder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.244 Global Other Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.245 Global Other Neurostimulation Devices Market for Overactive Bladder, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.246 Other Neurostimulation Devices Market for Overactive Bladder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.247 Other Neurostimulation Devices Market for Overactive Bladder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.248 Other Neurostimulation Devices Market for Overactive Bladder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.249 Other Neurostimulation Devices Market for Overactive Bladder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.250 Other Neurostimulation Devices Market for Overactive Bladder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.251 Other Neurostimulation Devices Market for Overactive Bladder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.252 Other Neurostimulation Devices Market for Overactive Bladder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.253 Other Neurostimulation Devices Market for Overactive Bladder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.254 Other Neurostimulation Devices Market for Overactive Bladder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.255 Other Neurostimulation Devices Market for Overactive Bladder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.256 Global Other Neurostimulation Devices Market for Heart Failure, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.257 Other Neurostimulation Devices Market for Heart Failure in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.258 Other Neurostimulation Devices Market for Heart Failure in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.259 Other Neurostimulation Devices Market for Heart Failure in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.260 Other Neurostimulation Devices Market for Heart Failure in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.261 Other Neurostimulation Devices Market for Heart Failure in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.262 Other Neurostimulation Devices Market for Heart Failure in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.263 Other Neurostimulation Devices Market for Heart Failure in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.264 Other Neurostimulation Devices Market for Heart Failure in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.265 Other Neurostimulation Devices Market for Heart Failure in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.266 Other Neurostimulation Devices Market for Heart Failure in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.267 Global Other Neurostimulation Devices Market for Sleep Apnea, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.268 Other Neurostimulation Devices Market for Sleep Apnea in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.269 Other Neurostimulation Devices Market for Sleep Apnea in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.270 Other Neurostimulation Devices Market for Sleep Apnea in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.271 Other Neurostimulation Devices Market for Sleep Apnea in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.272 Other Neurostimulation Devices Market for Sleep Apnea in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.273 Other Neurostimulation Devices Market for Sleep Apnea in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.274 Other Neurostimulation Devices Market for Sleep Apnea in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.275 Other Neurostimulation Devices Market for Sleep Apnea in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.276 Other Neurostimulation Devices Market for Sleep Apnea in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.277 Other Neurostimulation Devices Market for Sleep Apnea in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.278 Global Other Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.279 Global Other Neurostimulation Devices Market for Overactive Bladder, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.280 Other Neurostimulation Devices Market for Overactive Bladder in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.281 Other Neurostimulation Devices Market for Overactive Bladder in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.282 Other Neurostimulation Devices Market for Overactive Bladder in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.283 Other Neurostimulation Devices Market for Overactive Bladder in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.284 Other Neurostimulation Devices Market for Overactive Bladder in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.285 Other Neurostimulation Devices Market for Overactive Bladder in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.286 Other Neurostimulation Devices Market for Overactive Bladder in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.287 Other Neurostimulation Devices Market for Overactive Bladder in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.288 Other Neurostimulation Devices Market for Overactive Bladder in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.289 Other Neurostimulation Devices Market for Overactive Bladder in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.290 Global Other Neurostimulation Devices Market for Heart Failure, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.291 Other Neurostimulation Devices Market for Heart Failure in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.292 Other Neurostimulation Devices Market for Heart Failure in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.293 Other Neurostimulation Devices Market for Heart Failure in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.294 Other Neurostimulation Devices Market for Heart Failure in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.295 Other Neurostimulation Devices Market for Heart Failure in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.296 Other Neurostimulation Devices Market for Heart Failure in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.297 Other Neurostimulation Devices Market for Heart Failure in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.298 Other Neurostimulation Devices Market for Heart Failure in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.299 Other Neurostimulation Devices Market for Heart Failure in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.300 Other Neurostimulation Devices Market for Heart Failure in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.301 Global Other Neurostimulation Devices Market for Sleep Apnea, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.302 Other Neurostimulation Devices Market for Sleep Apnea in the US, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.303 Other Neurostimulation Devices Market for Sleep Apnea in Canada, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.304 Other Neurostimulation Devices Market for Sleep Apnea in the UK, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.305 Other Neurostimulation Devices Market for Sleep Apnea in Germany, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.306 Other Neurostimulation Devices Market for Sleep Apnea in France, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.307 Other Neurostimulation Devices Market for Sleep Apnea in Spain, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.308 Other Neurostimulation Devices Market for Sleep Apnea in Italy, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.309 Other Neurostimulation Devices Market for Sleep Apnea in Australia, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.310 Other Neurostimulation Devices Market for Sleep Apnea in China, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.311 Other Neurostimulation Devices Market for Sleep Apnea in Japan, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.312 Global MRI Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.313 Global MRI Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)
Table 18.314 Global MRI Non-Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)
Table 18.315 Global MRI Non-Compatible Neurostimulation Devices Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Volume)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.Abbott

  1. Abbott
  2. Aberdare Ventures
  3. Academy Medical Center
  4. Accelmed Growth Partners
  5. Action Potential Venture Capital
  6. AcuKnee
  7. AdvaStim
  8. Advent Life Sciences
  9. Aetion
  10. Aetna
  11. AG2R La Mondiale
  12. Alan Neuromedical Technologies
  13. ALC Healthcare
  14. Alere
  15. Aleva Neurotherapeutics
  16. Alfred Mann Foundation
  17. Allergan
  18. Allianz
  19. American Academy of Neurology
  20. American Academy of Pain Medicine
  21. American Medical Association 
  22. Amzak Health
  23. Andera Partners
  24. Anomali
  25. Antares Capital
  26. Anthem
  27. Aperture Venture Partners
  28. ARAG Group
  29. Atlante Ventures
  30. Atrotech
  31. Attivo Networks
  32. Aucta Technologies
  33. Autonomic Technologies
  34. Autonomix Medical
  35. Avery Biomedical Devices
  36. Aviva
  37. AXA PPP Healthcare
  38. Axilum Robotics
  39. Axiobionics
  40. Axonic Capital
  41. Axonics Modulation Technologies
  42. Banexi Ventures
  43. Barclays 
  44. Bayer
  45. BB Biotech Ventures
  46. BC Platforms
  47. Becton Dickinson
  48. Beijing PINS Medical
  49. Beijing Tiantan Hospital
  50. Biegler
  51. BioControl Medical
  52. BioElectronics
  53. Bioinduction
  54. BioMedical Life Systems
  55. BioMedPartners
  56. Bioness
  57. BioScience Managers
  58. BioWave
  59. BioWin
  60. BlueWind Medical
  61. Boston Scientific
  62. Brain State Technologies
  63. Brainlab
  64. BrainsGate
  65. BrainsWay
  66. b-to-v Partners
  67. Bupa
  68. Cala Health
  69. Calmare Therapeutics
  70. Canadian Agency for Drugs and Technologies in Health
  71. Cancer Prevention and Research Institute of Texas
  72. Capricorn Venture Partners
  73. Carbon Black
  74. Cardionomic
  75. Carlos III Health Institute
  76. Case Western Reserve University
  77. Caser Seguros
  78. Catholic University of Leuven
  79. CBC Banque & Assurance
  80. CEFALY Technology
  81. Celgene
  82. CensorNet
  83. Center for Sensorimotor Neural Engineering
  84. Centers for Medicare & Medicaid Services 
  85. Centripetal Networks
  86. Centro of Construction of Cardiac Stimulators of Uruguay
  87. Cerbomed
  88. Cerevast Medical
  89. Certara
  90. Cervel Neurotech
  91. Chattem
  92. Cibiem
  93. CICA
  94. Cigna
  95. Clearly Present Foundation
  96. Cleveland Clinic
  97. Clinakos
  98. Clinigen Group
  99. Cogentix Medical
  100. Coridea
  101. Cormorant Asset Management
  102. Cosman Medical 
  103. Covidien
  104. Crédit Mutuel Group
  105. CrowdStrike
  106. CVRx
  107. Cylance
  108. Darktrace
  109. Deep Brain Innovations
  110. Defense Advanced Research Projects Agency
  111. Deutsche Krankenversicherung
  112. DEYMED Diagnostic
  113. Dolphin Neurostim
  114. Dr. Langer Medical
  115. DyAnsys
  116. EaglePicher Medical Power
  117. EBS Technologies
  118. electroCore
  119. ElectroMedical Technologies
  120. Electronic Waveform Lab
  121. Elron Electronic Industries
  122. ELvation
  123. Endeavour Vision
  124. Endonovo Therapeutics
  125. EndoStim
  126. eNeura
  127. Enopace Biomedical
  128. Enspire DBS Therapy
  129. Epimed International
  130. ERGO Group
  131. Evergreen Medical Technologies
  132. Evidera
  133. Exabeam
  134. Expatriate Healthcare 
  135. F3F
  136. Federal Holding and Investment Company
  137. Finetech Medical
  138. FireEye
  139. Firstkind
  140. Fisher Wallace Laboratories
  141. Flashpoint
  142. Flatiron Health
  143. Flow Neuroscience
  144. Fogarty Institute for Innovation
  145. Forbion Capital Partners
  146. Forrestal Capital
  147. Fortinet
  148. Fountain Healthcare Partners
  149. Freedom Health 
  150. French National Authority for Health
  151. Frontcourt Ventures
  152. Functional Neuromodulation
  153. FundRx
  154. Gala Therapeutics
  155. Galvani Bioelectronics
  156. Generali Deutschland
  157. German Institute of Medical Documentation and Information 
  158. Gigamon
  159. Gilde Healthcare Partners
  160. GiMer Medical
  161. Gimv
  162. GlaxoSmithKline
  163. Gradient Medical
  164. Greatbatch
  165. Green Park & Golf Ventures
  166. GTX Medical
  167. Hannover Re 
  168. HBM Healthcare Investments
  169. HealthCore
  170. Helius Medical Technologies 
  171. Helpucover 
  172. HiDow 
  173. High-Tech Gründerfonds
  174. Hollywog
  175. Horowitz Group
  176. Humana
  177. Humanitas Clinical Institute
  178. ICON
  179. INC Research
  180. InCube Labs
  181. Indegene
  182. IndependiCare
  183. Ingress Health
  184. Initiative Capital Romandie
  185. INKEF Capital
  186. Innogest Capital
  187. Innovative Health Solutions
  188. Inspire Medical Systems
  189. Institute for Industrial Science
  190. Institute for Quality and Efficiency in Health Care 
  191. Institute for Hospital Remuneration System 
  192. Institute of Hospitalization and Care of Scientific Character
  193. Institute of Medical Arts
  194. InterWest Partners
  195. InterX Technologies
  196. IntraPace
  197. IPF Partners
  198. IQVIA
  199. iTENS
  200. Johari Digital Healthcare
  201. Johnson & Johnson
  202. JumpStart
  203. Kairuku
  204. Kaiser Permanente
  205. KCK Group
  206. Kinled Holding
  207. Kleiner Perkins
  208. La Luxembourgeoise
  209. LABORIE Medical Technologies
  210. Legend Capital Management
  211. Leonite Capital
  212. Lightstone Ventures
  213. Linguamatics
  214. LivaNova
  215. LogRhythm
  216. Lone Star Neuromodulation
  217. Longitude Capital
  218. LSP
  219. Lungpacer Medical
  220. MAAF Assurances
  221. MAG & More
  222. Magstim
  223. MagVenture
  224. Mainstay Medical
  225. Massachusetts Life Science Center 
  226. Mayo Clinic
  227. Mayo Foundation for Medical Education and Research
  228. McAfee
  229. McKesson
  230. MDC Partners
  231. Meagan Medical
  232. Medaffcon
  233. Med-Ally
  234. Medical University of South Carolina
  235. Medicines and Healthcare products Regulatory Agency
  236. Medi-Line
  237. Medisana
  238. MedSec
  239. Medtronic
  240. MEMStim
  241. Mercy
  242. Metavention
  243. Micro-Leads
  244. MicroTransponder
  245. Minnetronix
  246. Morgenthaler
  247. Munich Re 
  248. MyndTec
  249. National Agency for Medicines and Health Products Safety
  250. National Engineering Laboratory for Neuromodulation
  251. National Institute of Excellence in Health and Social Services
  252. National Institute of Health and Clinical Excellence
  253. National Institute of Medical Sciences and Nutrition Salvador Zubiran
  254. National Institutes of Health
  255. National Neuroscience Institute
  256. Nature's Gate
  257. NeoMed Management
  258. NeoSync
  259. Nervana Systems
  260. Netherlands Enterprise Agency
  261. Neuralieve
  262. neuroCare
  263. Neuroelectrics
  264. NeuroEM Therapeutics
  265. NeuroHabilitation
  266. NeuroMetrix
  267. Neuromod
  268. Neuronetics
  269. NeuroOne Medical Technologies
  270. NeuroPace
  271. NeuroQore
  272. NeuroRecovery Technologies
  273. Neuros Medical
  274. NeuroSigma
  275. NeuroTek Medical
  276. Neurova
  277. Neurowave Medical Technologies
  278. Nevro
  279. New Enterprise Associates
  280. Newronika
  281. Newton Biocapital
  282. Nexeon MedSystems
  283. Nexstim
  284. Nia Therapeutics
  285. Niveus Medical
  286. Novallia
  287. Novartis
  288. NTLab
  289. Nuvectra
  290. Nyxoah
  291. Ohio Third Frontier
  292. OMRON Healthcare
  293. OrbiMed Advisors
  294. Oregon Health & Science University
  295. Orthofix
  296. Osage University Partners
  297. Ottobock
  298. Oxford Finance
  299. Pain Alliance Europe
  300. PainPod BioTechnology
  301. Palantir
  302. Palo Alto Networks
  303. Parasym Health
  304. PAREXEL 
  305. PathMaker Neurosystems
  306. PerkinElmer
  307. Pharmaceuticals and Medical Devices Agency 
  308. PhysIOL
  309. Ping An Insurance
  310. PlatoScience
  311. Presidio Partners
  312. Principia SGR
  313. Prizm Medical
  314. ProtectWise
  315. Rainbow Medical
  316. Reeve Foundation
  317. Regional investment Company of Wallonia
  318. RenalGuard Solutions
  319. Renewal Technologies 
  320. ReShape Lifesciences
  321. Respicardia
  322. RITM
  323. Ritmedic
  324. Saama Technologies
  325. Saga Health Insurance 
  326. Saluda Medical
  327. Samsung Electronics America
  328. Sanderling Ventures
  329. Sanitas
  330. Santé Ventures
  331. Sapiens Steering Brain Stimulation 
  332. Scion NeuroStim
  333. SegurCaixa Adeslas
  334. Sensory NeuroStimulation
  335. SetPoint Medical
  336. Shape Security
  337. SHYFT Analytics
  338. Siemens
  339. Silicon Valley Bank
  340. Silk’n Therapy
  341. Smiths Medical
  342. Sofinnova Partners
  343. Sophos
  344. Soterix Medical
  345. Southern California Permanente Medical Group
  346. SPR Therapeutics
  347. St. Jude Medical (Abbott)
  348. StimGuard
  349. StimRelieve
  350. Stimwave
  351. SUBLIMED
  352. SUNMAS
  353. Synapse Biomedical
  354. Synergia Medical
  355. Syntilla Medical
  356. Tal Medical
  357. Tempus
  358. TENS Rx
  359. Theranica Bio-Electronics
  360. Threat Stack
  361. Thync
  362. Topspin Partners
  363. TraceSecurity
  364. Trustwave
  365. Tsinghua University 
  366. TYRX 
  367. Ultra Care Systems
  368. UnitedHealthcare 
  369. University of Brussels
  370. University of California
  371. University of Milan
  372. University of Minnesota
  373. University of New Mexico
  374. University of Pittsburgh
  375. University of Tokyo
  376. University of Washington
  377. US Department of Defense
  378. US Department of Homeland Security
  379. US Venture Partners
  380. USCI Japan
  381. VA Office of Research and Development
  382. Valencia Technologies
  383. Valtronic
  384. Vectra Networks
  385. Vention
  386. Venture Bank
  387. Versant Ventures
  388. Virility Medical
  389. Vision Sciences
  390. Vital Motion
  391. VitalityHealth 
  392. Wellington Partners
  393. Windham Venture Partners
  394. Wisconsin Alumni Research Foundation
  395. WISE
  396. Xavant Technology
  397. Yongjin Group
  398. Ysios Capital Partners
  399. Zenedge
  400. Zephyr Health
  401. ZOLL Medical
  402. ZTE
  403. Zynex Medical
     

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com